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Introduction 
Spasticity is defined as a motor disorder characterized by a velocity-dependent increase in 
muscle tone with exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex, as 
one component of the upper motor neuron syndrome [1]. The incidence of spasticity in patients with 
spinal cord injury is 65–78% [2]. In contrast, only around 35% of the patients with persistent 
hemiplegia after stroke manifest spasticity [3]. More specifically, the prevalence of spasticity is about 
19%  within three months after stroke, but rises to 39% after 12 months [4]. Spasticity commonly 
presents as muscle over-activity, reduction in the ability to relax, hypertonia, paresis, muscle spasms, 
and loss of the fine motor control, which are attributed to neural mechanisms [5]. However, less 
understood symptoms include increased stiffness in the soft tissue, muscle fatigue, and postural 
changes in the limbs, which may be explained by non-neural contributions having secondary effects 
on skeletal muscles [6, 7]. Lundstrom et al. postulate that spasticity cannot be considered an 
immediate consequence of CNS injury because it progresses during the weeks and months after the 
injury [8]. 
Several studies have demonstrated that muscular changes in spasticity cannot be explained by 
classic interpretations of the effects of neural changes alone [9, 10]. Crone et al. found that there is 
no correlation between the degree of spasticity (assessed by the Ashworth scale) and the degree of 
reduced "reciprocal inhibition" [11]. Gracies et al. proposed that muscular changes in spasticity 
cannot be fully explained by hyperreflexia or alterations in the central processing of sensory input in 
the spinal cord alone [12, 13]. Studies show that individuals presenting with spasticity after spinal 
cord injury on clinical examination turn out not to have any signs of hyperreflexia [14, 15]. In 
addition, it was shown that reflex stiffness did not differ significantly between the impaired spastic 
and the less impaired contralateral limb in individuals with spastic hemiparesis  [16]. It has therefore 
been argued that structural and functional changes in and around skeletal muscles may account for 
the late presentation of disabling spasticity after CNS injury. These changes range from rounding of 
the muscle fibers, increase in the inter-fiber space in hypertrophic fibers, and fiber atrophy which are 
all associated with deposition of excessive connective tissue in the muscle [17-20].  
 
Peripheral alterations in spasticity 
Several studies support the involvement of peripheral tissues, as muscle fibers and connective 
tissue, in spasticity.  Mirbagheri et al. found that intrinsic muscle stiffness was increased in patients 
with spasticity [21]. Wood et al. describe  the complex interactions between muscle cells and the 
extracellular matrix that affect the contractile properties of skeletal muscle fibers relevant to changes 
that occur with spasticity [22]. Lieber et al. showed that spastic muscle bundles are stiffer than isolated 
single spastic fibers; only about 40% of spastic muscle bundles were occupied by muscle fibers in 
contrast to 95% in normal muscle bundle, suggesting increased intramuscular connective tissue 
deposition in spastic muscle bundles [23].  Three different mechanisms have been proposed to explain 
the ‘increased resistance to stretch’ or intrinsic muscle stiffness [9]:  (1) active muscle stiffness where 
increased stiffness is caused by an increase in the number of cross-bridges attached during muscle 
contraction; (2) neurally-mediated reflex stiffness caused by descending influences on the 
monosynaptic reflex between muscle spindle afferents and the alpha motor neurons; and (3) passive 
muscle stiffness caused by fibrosis within the muscle tissue or a change in the properties of the muscle 
fibers.  
 
Active muscle stiffness: alterations in the extracellular matrix 
The extracellular matrix is composed by adipose cells, glycosaminoglycans and hyaluronic 
acid. Hyaluronic acid is however the chief component [24]. Immobilization or paresis decreases the 
normal turnover of the extracellular matrix, increasing its concentration within and between the 
muscular compartments. It is known that hyaluronic acid behaves like a non-Newtonian fluid at high 
concentrations and becomes more viscous [25]. The increased viscosity of the loose connective tissue 
may cause decreased gliding between the layers of collagen fibers, which may be perceived by 
patients as stiffness [26]. In a longitudinal study examining the effects of immobilization in rat soleus 
muscle, hyaluronic acid concentrations were increased and sarcomere length was shortened by one 
week [27]. These changes can lead to an increase in the number of cross-bridges attached during 
contraction [28, 29], producing active muscle stiffness. Note that at this stage the arrangement of 
collagen fibrils in the endomysium is still longitudinal, but becomes more circumferential by 4 weeks 
[27]. It is known that under homeostatic conditions hyaluronic acid has important roles in tissue 
structural integrity. However, a series of events that leads to muscle contracture may begin with subtle 
changes in the turnover of hyaluronic acid [30, 31] and the properties of the extracellular matrix very 
early on after CNS injury (Fig. 1).  
 
 
FIG. 1. Proposed model of the evolution of the spastic process. 
We hypothesize that the non-Newtonian behavior of hyaluronic acid may be especially 
responsive to injection of hyaluronidase enzyme that depolymerized it and lower molecular mass 
polymers are generated [30]. Stern et al. found that small polymers of hyaluronic acid, smaller than 
1000 Dalton, may be able to catalyze specific inflammatory reactions [31]. Thus biochemical control 
of the properties of hyaluronic acid early on may help restore the quality of hyaluronic acid and re-
establish normal tissue sliding mechanisms involving the endomysium, perimysium, epimysium and 
deep fascia.  
 
Neurally-mediated muscle stiffness: the role of muscle spindles 
The muscle spindles are enclosed in a capsule and have both sensory and motor components. 
The motor component consists of several small specialized muscle fibers known as intrafusal fibers, 
localized at either end of the muscle spindle. The sensory component is localized in the central area 
of the spindles, where specialized nerve endings termed annulospiral and flower-spray endings are 
present. The annulospiral endings (Ia afferents) provide information about the length and velocity of 
muscle contraction, whereas the flower spray endings (group II afferents) only provide information 
on muscle length but these sensory fibers respond even when the muscle is at rest.  When the muscle 
lengthens and the muscle spindle is stretched, mechanically-gated ion channels in the sensory 
dendrites are opened. This leads to a receptor potential that triggers action potentials in the muscle 
spindle afferents; the firing of the spindle Ia afferents stimulates the alpha motor neurons in the spinal 
cord causing  reflex contraction of the extrafusal muscle fibers. At the same time Ia spindle afferents 
synapse in the posterior horn of the cord and stimulate inhibitory interneurons which then depress 
alpha motor activity to the antagonistic muscles. Thus the simple myotatic/stretch reflex acts as a 
servo-mechanism to maintain correct muscle tone. Muscle tone (residual muscle tension or tonus) is 
the continuous and partial contraction of the muscles, or the muscle’s resistance to passive stretch 
during rest. If the muscle spindles cannot be activated or are activated too easily, the regulation of 
muscle tone will be compromised [5, 32, 33].  
When the relationship between muscle spindles and the intramuscular connective tissue is 
considered, the role of the muscle spindles in peripheral motor coordination becomes evident. The 
muscle spindles are localized in the perimysium and their capsule is connected to the epimysium and 
fascial septae [34, 35]. Strasmann et al. analyzed the septum of the supinator muscle and found that 
many muscle spindles are inserted directly into the connective tissue of the septum [36]. Studies have 
demonstrated that the extra- and intra-fusal muscle fibers possess complex biophysical properties that 
contribute to muscle stiffness and/ or laxity [37, 38]. Increased stiffness of connective tissue in an 
immobilized muscle reduces its compliance. This in turn increases spindle stimulation to a given 
stretch, as the pull is transmitted more efficiently to the spindles in a less extensible muscle [39]. Such 
increase in spindle responses has been demonstrated after immobilization in a shortened position, 
which augments stretch reflexes and eventually contributes to the stretch-sensitive forms of muscle 
overactivity [40-42]. Thus Gracies proposed that the etiology of spasticity involves increased stretch-
induced stimulation of spindles in muscles with stiffer connective tissue (endomysium, perimysium 
and epimysium), which contributes to abnormal feed-back and feed-forward control of the extrafusal 
muscle fibers [43].  However, the relative contribution of intrinsic muscle stiffness versus neurally-
mediated spindle responses may vary by body region affected [44].  
It is commonly noted that voluntary movements that stretch a spastic muscle produce a reflex 
in the antagonistic muscle opposing the initiating movement [45]. Constant overuse of spastic 
antagonist muscles can augment the production [46], and retention [47] of hyaluronic acid in the 
connective tissue. The increased concentration of hyaluronic acid on the spread surface can lead to 
its further self-association, leading to dramatically increased viscoelasticity [48]. The higher viscosity 
extracellular matrix can alter the perimysium as well the muscle spindle capsule leading to hyper 
stretching of the annulospiral ring, and further decrease the threshold of activation of the spindle 
afferents and the alpha motoneuron with increasing spasticity in the corresponding motor unit. In fact 
Beres-Jones [49] has demonstrated that repetitive clonic muscle contractions are more likely to be 
associated with impaired interaction of central and peripheral mechanisms than with recurrent stretch 
reflex activity. Elderly individuals however often show a decrease in basal tone and in reflex activity, 
perhaps due to sarcopenia and consequent alterations in muscle tone and muscle spindle activation 
[50]. Disabling spasticity occurs more commonly in young survivors (less than 65 years) or after a 
first stroke [51], further necessitating that we understand the mechanisms and initiate appropriate 
treatment early.  
 
Passive muscle stiffness: deposition of collagen and fibrosis 
In the chronic phase, histolopathological studies show a generalized increase in extracellular 
connective tissue in spastic muscles; specifically an increase in the concentration of collagen [18, 19]. 
Stecco C. at al. reported similar findings in patients after 10 months of immobilization that could 
simulate the period of flaccid paralysis after CNS injury [52]. The authors dissected several recently 
amputated legs of patients that had been immobilized with a tibio-femoral external fixator due to 
severe trauma to the knee region. They showed the existence of fibrotic zones in the subcutaneous 
tissue that created adherences between the skin and deep fascia in the ankle region, which had not 
been injured. The entire ankle region demonstrated alterations in the subcutaneous tissue, and the 
deep fascia showed disorganized arrangement of the fibrous bundles. Histological study showed that 
the loose connective tissue separating the subcutaneous planes was absent, and that all the structures 
were replaced by homogeneous fibrous tissue. Studies by Järvinen et al. [53] reveal that 
immobilization results in a marked increase in the endo- and perimysial connective tissue of the 
muscle, the majority of the increased endomysial collagen being deposited directly on the sarcolemma 
of the muscle cells. The connective tissue becomes very dense and the number of irregularly oriented 
collagen fibers is markedly increased. Further, immobilization clearly disturbs the normal structure 
of the endomysium making it impossible to distinguish the various networks of fibers from one 
another. One might hypothesize that similar findings would be seen in individuals with chronic stroke. 
In fact the presence of dense connective tissue (fibrosis) has been recently confirmed through 
ultrasonography by Picelli et al. [54]. The authors quantified the disruption of normal muscle 
architecture in spastic muscles by evaluating and grading muscle echo intensity. The hyper 
echogenicity in the muscle in the chronic stage is due to increase in collagen fiber both within and 
between the muscle bundles (Fig. 2). Excessive collagen deposition is thought to lead to the 
development of abnormal postures, and greater amounts of collagen predict a lower response to 
conventional treatments for spasticity such as Botulinum toxin injections.  
 
FIG. 2. Ultrasonography and elastosonography (to assess tissue stiffness) imaging in a spastic tibialis 
anterior muscle. 
Although muscle fibers are the main tissues studied in spasticity, there is no agreement on the 
role of muscle fiber pathology and abnormal muscle activity in spasticity [9, 23]. Muscle biopsies 
from patients with spasticity show abnormalities such as increased variability in fiber size, increased 
numbers of ‘rounded’ fibers, and ‘moth-eaten’ fibers [17, 20, 55, 56]; these are however non-specific 
changes also noted in other disease states, and may be directly attributed to the effect of 
immobilization. Morphometric and histochemical investigations show changes in mechanical muscle 
fiber properties [17, 28, 57] that might contribute to spastic muscle tone, indicating an increase in 
passive stiffness of a muscle to stretch in patients with stroke and spasticity due to subclinical 
contractures. Indeed studies have found that functional alterations in patients with muscle hypertonia 
are associated with subclinical muscle contracture rather than with reflex hyper-excitability [6, 13, 
16, 58-60]. Thus the data are congruent with the idea that instead of spasticity causing contracture, 
contracture may actually potentiate spasticity in some patients [59]. Consequently, the Ashworth 
scale and modified Ashworth scale remain low-sensitivity instruments for distinguishing between 
soft tissue and neural contributions to hypertonia [61]. Electromyographic measurements can quantify 
the resistance to passive movement, but are still unable to determine how much resistance is produced 
by the tonic stretch reflex and how much is produced by soft tissue stiffness [5]. 
 
Role of peripheral mechanisms in generating pain 
Post-stroke spasticity is often associated with secondary complications such as pain and 
limitation in mobility. Motor and sensory impairments are associated with an increased risk for 
stroke-related pain [8]. Patients with spasticity produce compensatory movements and postures due 
to changes in their muscles and soft tissues. Such compensations are also noted with common 
musculoskeletal dysfunction. Indeed Stecco at al. have documented alterations in the soft tissue and 
muscle in patients with chronic myofascial pain [26], and have correlated the alteration in the loose 
connective tissue of the deep fascia with patients’ stiffness and pain. The connective tissue is well 
innervated with free nerve endings and proprioceptors as Pacini and Rufini corpuscles [62-64]. It has 
been shown that change in the visco-elasticity of the connective tissue shapes the dynamic response 
of the mechanoreceptors in the tissue, which may become the source of pain [65, 66]. Thus there may 
be greater similarities between non-specific musculoskeletal pain and spastic muscle pain.  
Implications for treatment 
Surgical, pharmacological, and physiotherapy techniques are among the most common  interventions 
offered to mediate spasticity [67,68]. Pharmacological agents are the most commonly used 
intervention to treat poststroke spasticity. The options for reducing spasticity are oral medication, 
such as benzodiazepines, baclofen, tizanidine hydrochloride, and dantrolene.  Diazepam is one of the 
oldest and most commonly used benzodiazepines for treating spasticity. Botulinum toxin type A is 
used for focal treatment of overly spastic muscles, while Intrathecal baclofen is commonly used to 
reduce spasticity in individuals with spinal cord injury. However, despite significantly reducing 
spasticity, the use of pharmacological agents does not always translate into an increase in 
functionality [69], but also make the muscles weak [12]. As a result, restoration of active movement 
and function may be compromised.  
While the changes in muscle structure may be partly attributed to immobility ensuing from the 
initial neurologic injury, the changes in function cannot be explained by classic interpretations of the 
effects of neural changes alone. Here we propose a novel hypothesis to explain the role of non-neural 
factors in the development and exacerbation of spasticity, and describe a new treatment approach 
based on this hypothesis in the case series below.  
 
The hyaluronan hypothesis 
We hypothesize that immobility, after central nervous system injury, increases the viscosity of 
hylauronan in the extracellular matrix due to its non-newtonian properties. The increased viscosity 
leads to stiffness of the loose connective tissue in and around the muscles and increases tension in the 
force transmitted by the dense connective tissue (including the endomysium, perimysium and 
epimysium) reducing its compliance. The capsule of the muscle spindle is a specialized portion of the 
epimysium and is continuous with the perimysium [70]. Thus reduced perimysial compliance will 
increase spindle stimulation and spindle response to a given stretch-force, as the stretch will be more 
efficiently transmitted to the spindles in a less extensible muscle producing hyperreflexia (Fig. 2a).  
  
Fig 2a: muscle spindle mechanism 
 
If immobility continues, self-association of the chains of hyaluronan will dramatically increase 
the viscoelasticity of the extracellular matrix in and around the muscles producing generalized muscle 
stiffness. The stiffness and spasticity may predominate in some muscles such as the pectoralis major, 
the biceps brachii, pronator teres and wrist and finger flexors of the upper limb because these muscles 
have large myofascial expansions that connect them together leading to posturing of the joints in 
flexion (Fig. 2b).  
 
 
Fig 2b: dysfunction of the muscle spindle 
 
Untreated and unchecked the abnormal chronic posturing can lead to fibrosis and contracture. On 
the other hand, voluntary movement that stretches a spastic muscle will produce a reflex in the 
antagonistic muscle to oppose the voluntary movement [71], further stimulating specific cells in the 
loose connective tissue called fasciacytes to produce more hylauronan [46]. The aggregation of the 
hyaluronan will  disturbed balance of forces between the agonist and antagonist muscles leading to 
co-contraction, excessive torques during movement and muscle fatigue. The hyaluronan hypothesis 
can thus mechanistically partially explain the clinical presentations of individuals with spasticity.   
The purpose of this case series is to describe the safety, tolerability, and preliminary efficacy of human 
recombinant hyaluronidase-saline injections given intramuscularly to restore the viscosity of the 
extracellular matrix and reduce muscle stiffness in individuals with unilateral spastic hemiparesis 
from a brain injury. Human recombinant hyaluronidase is FDA approved since 2005 as a tissue 
permeability modifier. While it is recommended that hyaluronidase be used for subcutaneous 
injections only, Moore DC [73] reports as many authors have performed nerve blocks entailed 
injections into muscle layers and deep fascial compartments. Moore DC concluded, in his review, 
that there is no contraindication to infiltrating solutions containing hyaluronidase into deep tissues if 
the normal precautions for intravascular injections are observed. Hyaluronidase is supplied as a 
sterile, clear, colorless, non-preserved, ready-for-use solution. Each mL contains 150 USP units of 
recombinant human hyaluronidase with 8.5 mg sodium chloride, 1.4 mg dibasic sodium phosphate, 
1 mg albumin human, 1.5 mg L-methionine, 0.2 mg polysorbate 80, and hydrochloric acid and sodium 
hydroxide added for pH adjustment; it has a pH of ~7.0 and an osmolality of 280 to 340 mOsm/kg.  
Hyaluronidase modifies the permeability of connective tissue through the hydrolysis of hyaluronan 
by splitting the glucosaminidic bond between C1 of an N-acetylglucosamine moiety and C4 of a 
glucuronic acid moiety. This temporarily decreases the viscosity of the extra cellular matrix.  
 
Injection with recombinant hyaluronidase 
From May 2014 to September 2015, twenty-one individuals (14 male and 7 female) between the 
ages of 10 and 77 years with moderate-to-severe upper limb spasticity in more than one joint 
consented to received off-label injections of recombinant hyaluronidase in combination with 
preservative-free normal saline, in the outpatient hand clinic at the Hospital for Joint Diseases, New 
York University Langone Medical Center. The individuals were existing patients that had exhausted 
all available options with limited benefit, or were referred to the clinic by providers seeking this 
specific treatment. The institutional review board approved the case series, and the study was 
registered in Clinicaltrials.org. All procedures were performed in accordance with the Guidelines for 
Good Clinical Practice as issued by the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use. The investigation and the use of 
patient data for research purposes were in accordance with the Declaration of the World Medical 
Association, and the study was performed in accordance with ethical standards on human 
experimentation as per the Helsinki Declaration. 
The inclusion criteria for the present case series were: informed consent for the procedure and for 
documentation of video recordings of range-of-motion (ROM) for clinical and academic purposes, 
unilateral brain injury producing the upper motor neuron syndrome, moderate-to-severe spasticity 
with a Modified Ashworth Scale (MAS) score of ≥2 in more than one joint. Exclusion criteria were 
severe sensory aphasia, bilateral spasticity making it difficult to comply with a home exercise 
program involving assistance with the unaffected limb, concurrent treatment of spasticity with other 
injectable agents such as Botulinum toxin injections, recent changes in the treatment of spasticity or 
in underlying medical problems. The 21 cases are described in Table 1.  
 
Case # Age Sex Side  Etiology 
Time since injury (months) Prior treatments 
No. of units of Hyaluronidase used* 
Volume injected (ml) 
No. of areas injected Location of injections 
1 67 M R 1 29 BT 450 6 0 
Pectoralis minor, triceps, pronator theris, extensor digitorum communis, extensor carpi ulnaris, flexor carpi radialis. 
2 48 F R 2 64 BT 450 6 0 
Pectoralis minor, pronator theris, extensor digitorum communis, flexor digitorum, extensor carpi ulnaris, flexor carpi radialis. 
3 59 M L 1 61 BT 450 6 0 
Pectoralis minor, pronator theris,  extensor digitorum communis, flexor digitorum, extensor carpi ulnaris, flexor carpi radialis. 
4 53 F L 2 54 BT 450 6 7 
Pectoralis minor,pronator theris,   bicept brachi, extensor digitorum communis, extensor carpi ulnaris, flexor carpi radialis, abductor pollicis 
5 66 M R 2 41 BT 450 6 0 
Pectoralis minor,  pronator theris, bicept brachi, extensor digitorum communis, extensor carpi ulnaris, flexor carpi radialis. 
6 43 F L 1 45 none 450 6 0 
Pectoralis minor,  pronator theris, extensor digitorum communis, brachialis, flexor digitorum,  palmaris aponevrosis 
7 43 M R 1 10 BT 600 8 0 
Pectoralis minor, pronator theris,  teris major,  extensor digitorum communis,  flexor digitorum,  palmaris aponevrosis, extensor carpi ulnaris, flexor carpi radialis, 
8 59 M R 1 24 BT 600 8 0 
Pectoralis minor, pronator theris,  teris major,  extensor digitorum communis,  flexor digitorum,  palmaris aponevrosis, extensor carpi ulnaris, flexor carpi radialis, 
9 64 M R 2 85 none 600 8 0 
Pectoralis minor,  pronator theris, bicep brachi, extensor digitorum communis,  flexor digitorum,  palmaris aponevrosis, extensor carpi ulnaris, flexor carpi radialis, 
10 15 M R 1 5 none 600 8 0 
Pectoralis minor,   biceps brachi, brachialis, pronetor theris, flexor digitorum, extensor digitorum communis,    palmaris aponevrosis,  flexor carpi ulnaris, 
11 11 F L 6 114 BT 450 6 0 
Pectoralis major,   biceps brachi, pronetor theris, flexor digitorum,    palmaris aponevrosis,  flexor carpi ulnaris, estensor carpi radialis 
12 38 F R 1 18 none 600 8 0 
Pectoralis minor,   biceps brachi, brachialis, pronetor theris, flexor digitorum, extensor digitorum communis,    palmaris aponevrosis,  flexor carpi ulnaris, 
13 10 M R 1 152 BT 300 4 0 
Pectoralis minor,   biceps brachi, flexor digitorum, flexor carpi radialis,  extensor digitorum communis,  flexor carpi ulnaris. 
14 39 M L 1 35 BT 450 6 0 
Pectoralis minor,   biceps brachi, brachialis, pronetor theris, extensor digitorum communis,    palmaris aponevrosis,  flexor carpi ulnaris,  interosseus III-IV and IV-V 
15 11 M R 4 8 none 450 6 0 
Pectoralis minor,   biceps brachi,  extensor digitorum communis,    palmaris aponevrosis, flexor digitorum,  flexor carpi ulnaris,  flexor carpis radialis, interosseus III-IV and IV-V 
16 10 F R 2 17 none 300 4 0 
Pronator theris, brachialis,  extensor ulnaris carpi,  flexor digitorum,  hypothenar eminance  
17 15 F R 4 13 BT 600 8 0 
Elevetor scapule, Pectoralis minor,   biceps brachi, brachioradialis, pronetor theris, flexor digitorum, extensor digitorum communis, extensor carpi radialis,  flexor carpi ulnaris,  palmaris aponevrosis, 
18 58 M R 2 12 none 600 8 0 
Romboid minor, pectoralis minor,   biceps brachi,  brachialis, pronetor theris, flexor digitorum, extensor digitorum communis,   flexor carpi ulnaris,   
19 77 M L 1 19 none 450 6 0 
poster part of the deltoid, pectoralis minor,  pronetor theris, extensor digitorum communis,   flexor carpi radialis,   
20 59 M R 2 5 BT 600 8 0 
 pectoralis minor,   biceps brachi,  brachialis, pronetor theris, flexor digitorum, extensor digitorum communis,   flexor carpis radialis, palmaris aponevrosis 
21 37 M R 4 7 BT 600 8 0 
Elevetor scapule,  pectoralis minor,   brachialis, pronetor theris, flexor digitorum, extensor digitorum communis,  flexor carpi ulnaris, abductor pollicis,  palmaris aponevrosis 
           
m.v. 42 15 M 15 R  38.95  500 6.67 0.33  
S.D. 21.98 6 F 6 L  38.79  98.74 1.32 1.53   
Table 1: location and amount of medicine used in each single patient. BT= botulinum toxin injection. 1= 
ischemic stroke; 2=hemorrhagic stroke; 3= cancer; 4=Sturg Weber (hemicraniectomy for hemispherectomy) 
 
The dose of hyaluronidase was determined according to the each patient’s individual pattern and 
extent of spasticity, with the total dose not exceeding 600 IU and not more than 75 IU per single 
injection site in this cohort. The dosage of hyaluronidase selected for the patients were between four 
and eight times more than normal therapeutic dose, but still nontoxic based on the ratio of toxicity 
that is 200,000 to 1 [74]. The dilution was standardized: one vial (150 IU) was diluted with 1 ml 
normal saline, thus each ml of injected fluid contained ~ 75 IU of hyaluronidase. This dilution was 
selected based on the rate of diffusion, that is proportionate to the amount of enzyme, and the rate of 
extent, that is proportionate to the volume of solution [75].  Prior to the procedure a preliminary skin 
test for hypersensitivity to recombinant Hyaluronidase was performed. An intradermal injection of 
approximately 0.02 mL (3 Units) of a 150 Unit/mL solution was injected. No erythema, itching or 
wheal were noted in and around the injection site at 5 or 20 minutes in any of the patient’s injected. 
All injected areas were cleaned with chloroprep swabs prior to injecting. The injections were 
administered using sterile aseptic technique by a single operator with a 0.7 mm 30G needle. Surface 
anatomical landmarks [76] were used to guide the location of the muscles injected and precautions 
were taken to avoid intravascular injection. Multiple synergic muscles, in one or more spatial planes, 
were injected in the upper limb to address stiffness along the myofascial chain as shown in Fig. 3.  
 
   
Fig 3: location of the injections 
 
All the patients were evaluated pre-injection, and at three time points post-injection: between 3-
10 days, 4-6 weeks and 12-15 weeks. Safety was assessed by examination for adverse events and 
clinically significant changes in vital signs (body temperature, diastolic and systolic pressure, heart 
rate) post-injection and over the period of follow-up for at least up to 15 weeks for this case series, 
and for longer in most cases. Adverse events were sought through interviews, during which patients 
were encouraged to report any problems. Each patient was assessed by the same treating physician at 
study entry and throughout the course of the study. All complaints were also assessed by an unbiased 
clinic nurse and documented in the medical record. Patients were allowed to continue with current 
therapy and encouraged to follow a home exercise program of stretching and passive movements of 
the upper limb joints to prevent further muscle stiffness. Compliance with the home exercise program 
was documented in the medical record. 
Efficacy of treatment was assessed by change in spasticity on the MAS, and in passive and active 
ROM measured from video recordings. ROM of shoulder abduction and forearm pronation and 
supination (in the frontal plane) and shoulder forward flexion, elbow flexion and extension, and wrist 
flexion and extension (in the sagittal plane) were recorded with the camera placed perpendicular to 
the plane of the movement. Each movement was repeated three times passively, and when possible, 
actively. Angular excursions of the joints were extracted using commercially available video analysis 
software (Dartfish 7.0), which has been shown to be a viable and reliable method for quantitative 
clinical movement analysis with a reported interclass correlation coefficient (ICC) of 0.45 to 0.94 
[77].  
The regions of the injections were focused in relation at the limitation presented by the patients. 
For this reason, it was decided to focus the injection for restore ROM that was less than 85% of the 
normal range reported by American Association of Orthopedic Surgeon (AAOS). For the same reason 
the dates of the active and passive ROM that reach the 85% of the normal range at baseline  were 
excluded from our statistical evaluation. For the passive ROM we increment the limit to 95% for 
elbow extension; 90% elbow flexion; 100% forearm pronation and supination and wrist flexion due 
to the good ROM presented by most of the patients at baseline. The evaluation of the supination and 
pronation were performed from a frontal position with the camera at the level of the forearm, 20 cm 
from the hand. The landmark for evaluate the pronation and supination was the line between the head 
of the II and V metacarpal bone. The force of the operator was applied at the level of the wrist. This 
procedure has generated a bias increasing the axial rotation of the hand of the patients. For this reason 
it was decided to decrease of 15% all the values of the pronation and supination in all the evaluations. 
 
Role of the funding source 
There was no funding for this case series 
 
Statistical analysis 
Data analysis was performed by using the SPSS statistical package (version 20.0) for Windows. 
Motor tests were analyzed as change from baseline at 1, 4 and 12-15 weeks with Wilcoxon signed-
rank test. 
The changes at post-baseline visits were calculated for each assessment of motor function. Statistical 
testing was done to assess whether the absolute change and, where applicable, percentage change 
from baseline and each postoperative visits was significantly different from zero. The Wilcoxon 
signed-rank test was used to test whether changes in the clinical global impression of severity score 
and clinical global impression of improvement score at each postoperative visits were significantly 
different from baseline.  
Efficacy was defined as a significant (p<0.05) reduction in spasticity from baseline.  
 
Results: 
All patients tolerated the injections without immediate adverse effects. None of the patients 
demonstrated a hypersensitivity reaction to the skin test. Patients 1-5 were followed daily for the first 
3 days after the injections for close monitoring and to examine onset of therapeutic effect, if any. The 
most common adverse reaction was soreness at the injection sites with onset 24 hours after the 
injection, lasting 24-48 hours. Sun exposure caused a mild rash in the injected arm on days 1-3 which 
disappeared spontaneously. Thereafter patients were advised to avoid direct sun-exposure for the first 
week after the injections.  
Patients reported reduction in muscle stiffness as early as 2-3 days post-injection, once the post-
injection soreness wore off. The stiffness reduced further over the subsequent weeks. Compliance 
with the home exercise and stretching program facilitated reduction in stiffness. All 21 patients 
showed clinically significant reduction in spasticity on the Modified Ashworth Scale in all the upper 
limb joints 1 week post-injection (T1) which persisted at 1 month (T2) and 3-month (T3) follow up 











2nd  FU 
(T3)  PRE POST 1 FOLL 2 FOLL 
mean 
value 2.41 0.82 0.65 0.56 2.47 0.79 0.63 0.56 
SD (+/-) 0.80 0.73 0.70 0.73 0.77 0.79 0.76 0.78 
P value    0.00 0.00 0.00   0.00 0.00 0.00   T0-T1 T0-T2 T0-T3   T0-T1 T0-T2 T0-T3 
  ELBOW 
  FLEXION EXTENSION 
  PRE POST 1 FOLL 2 FOLL PRE POST 1 FOLL 2 FOLL 
mean 
value 2.29 0.64 0.67 0.60 2.31 1.05 1.02 0.98 
SD (+/-) 0.56 0.76 0.84 0.80 0.51 0.65 0.78 0.77 
P value    0.00 0.00 0.00   0.00 0.00 0.00   T0-T1 T0-T2 T0-T3   T0-T1 T0-T2 T0-T3 
  FORARM 
  PRONATION SUPINATION  
  PRE POST 1 FOLL 2 FOLL PRE POST 1 FOLL 2 FOLL 
mean 
value 2.28 0.85 0.65 0.53 2.28 0.80 1.00 0.89 
SD (+/-) 0.60 1.04 0.88 0.70 0.60 1.06 1.08 0.99 
P value    0.00 0.00 0.00   0.00 0.00 0.00   T0-T1 T0-T2 T0-T3   T0-T1 T0-T2 T0-T3 
  WRIST 
  FLEXION EXTENSION 
  PRE POST 1 FOLL 2 FOLL PRE POST 1 FOLL 2 FOLL 
mean 
value 2.35 0.47 0.47 0.38 2.41 0.65 0.91 0.97 
SD (+/-) 0.49 0.62 0.72 0.62 0.51 0.79 0.87 0.94 
P value    0.00 0.00 0.00   0.00 0.00 0.00   T0-T1 T0-T2 T0-T3   T0-T1 T0-T2 T0-T3 
 
Table 2: Modify Ashword Scale. (SD= standard deviation) 
 
The mean passive range of motion increased for shoulder flexion, abduction and wrist extension 
at 1 week post-injection and persisted at approximately the same level at 1 and 3 month follow up. 
The increase in elbow flexion, forearm pronation and wrist flexion was more modest at 1 week post 
injection and regressed slightly over subsequent follow up. Elbow extension and forearm supination 
also increased, but much more variably across patients at 1 week post-injection but became 
statistically significant over subsequent follow up, especially at 3 months (Table 3).  
   
SHOULDER 
FLEXION ABDUCTION 
PRE POST 1 FOLL 
2 






value 114.44 129.50 131.00 126.72 114.61 134.50 141.22 135.78 
SD (+/-) 25.34 28.36 26.67 26.96 28.80 33.75 34.50 29.46 
p value    0.00 0.00 0.01   0.00 0.00 0.00 T0-T1 T0-T2 T0-T3 T0-T1 T0-T2 T0-T3 
 ELBOW 
 FLEXION EXTENSION 










value 128.1 133.5 132.3 130.6 161.89 168.33 167.11 168.56 
SD (+/-) 6.45 7.88 10.34 10.82 12.98 15.63 14.61 14.78 
p value    0.05 0.19 0.23   0.13 0.14 0.05 T0-T1 T0-T2 T0-T3 T0-T1 T0-T2 T0-T3 
 FORARM 
 PRONATION SUPINATION  










value 78.07 85.71 85.64 81.21 71.44 83.89 80.67 81.11 
SD (+/-) 13.10 14.25 13.30 12.90 23.42 14.64 22.30 20.64 
p value    0.01 0.03 0.46   0.10 0.05 0.02 
T0-T1 T0-T2 T0-T3 T0-T1 T0-T2 T0-T3 
 WRIST 
 FLEXION EXTENSION 










value 67.86 76.57 75.36 74.43 39.12 55.35 53.71 55.71 
SD (+/-) 12.85 14.63 17.31 16.36 12.37 20.07 16.55 17.12 
p value    0.01 0.09 0.10   0.00 0.00 0.00 T0-T1 T0-T2 T0-T3 T0-T1 T0-T2 T0-T3 
 
Table 3: Passive Range of motion of the patients in degree. (SD= standard deviation) 
 
The mean active range of motion showed more variability across patients, but increased 
significantly for shoulder flexion, shoulder abduction, elbow extension, forearm supination  and wrist 
extension at 1 week post injection and the improvement was generally maintained at 3 months. The 
increase in wrist extension became statistically significant at 1 month rather than at 1 week and 
persisted at 3 months. Interestingly, active elbow flexion and forearm pronation showed the greatest 
amount of variability across patients which decreased over time, but did not show statistically 





PRE POST 1 FOLL 2 FOLL PRE POST 1 FOLL 2 FOLL 
mean 
value 75.21 99.21 94.71 101.71 88.80 102.53 101.67 105.73 
SD (+/-) 51.04 39.66 54.32 48.01 30.11 33.05 38.15 37.12 
p value   0.006 0.005 0.004   0.032 0.070 0.062 T0-T1 T0-T2 T0-T3 T0-T1 T0-T2 T0-T3 
 ELBOW 
 FLEXION EXTENSION 
 PRE POST 1 FOLL 2 FOLL PRE POST 1 FOLL 2 FOLL 
mean 
value 125.00 129.90 131.00 129.60 124.43 141.57 144.86 146.57 
SD (+/-) 9.39 13.49 12.87 8.47 30.07 26.71 29.27 28.33 
p value   0.230 0.259 0.273   0.047 0.086 0.094 T0-T1 T0-T2 T0-T3 T0-T1 T0-T2 T0-T3 
 FORARM 
 PRONATION SUPINATION  
 PRE POST 1 FOLL 2 FOLL PRE POST 1 FOLL 2 FOLL 
mean 
value 43.27 46.33 46.47 53.27 22.93 35.00 41.36 35.43 
SD (+/-) 31.05 41.98 36.05 18.61 45.98 45.20 43.54 46.66 
p value   0.660 0.610 0.254   0.022 0.011 0.005 T0-T1 T0-T2 T0-T3 T0-T1 T0-T2 T0-T3 
 WRIST 
 FLEXION EXTENSION 
 PRE POST 1 FOLL 2 FOLL PRE POST 1 FOLL 2 FOLL 
mean 
value 32.71 41.79 47.21 48.64 -0.07 13.50 16.36 14.50 
SD (+/-) 25.09 23.81 18.72 21.95 29.42 24.73 25.52 25.71 
p value   0.036 0.004 0.046   0.076 0.038 0.056 T0-T1 T0-T2 T0-T3 T0-T1 T0-T2 T0-T3 
 
Table 4: Active Range of motion of the patients in degree. (SD= standard deviation) 
 
Discussion: 
In this case series, 21 patients with moderate-to-severe chronic upper limb spasticity received 
multiple intramuscular human recombinant hyaluronidase-saline injections and were followed-up for 
12-15 weeks. The injections were  found to be safe and well tolerated. Spasticity was significantly 
reduced across all the joints in the entire upper limb and the improvement was maintained throughout 
the follow up period. Although there were significant inter-individual differences, significant 
improvements in passive range of motion, and remarkably also in active range of motion, were noted 
at several joints which were maintained over the follow up period. These results provide preliminary 
evidence in support of the hyaluronan hypothesis of spasticity.  
The long lasting decrease of the HA viscosity cannot be related at the single effect of the drug 
due to it short effect. Indeed Hechter [78] found that the natural HA barrier was partly restored in 
twenty-four hours and completely restored in forty-eight [79]. At the opposite our results show an 
improvement of the ROM at 48 hours and later. We suppose that a normalization of the viscosity of 
the deep fascia and perimysium, that surround the muscle spindle, should restore the normal 
activation of the primary and secondary sensory fibers, decreasing the activation of the alfa motor 
neuron. We also believe that this decrease of the muscle tone, following the normalization of the 
activity of the muscle spindle, should not last so long without the contemporary treatment of the 
synergic and antagonist muscle belly. It is postulated that the tension generated by the hyper tonicity 
of the primary spastic muscle can affect, thought the "myofascial expansion" [80], synergic mono or 
biarticular muscle in the same segment, or in the proximal / distal segments. In our previous 
publication [81] it was proposed that, from an active muscle stiffness, generated by the CNS lesion, 
we can have a new neurally mediated reflex stiffness that can involve muscles that perceive the 
tension generated thought the "myofascial expansion". Overall Kaper DG [45] showed that a 
voluntary movement stretching a spastic muscle may produce a reflex in the antagonistic muscle that 
would oppose the voluntary movement. This constant overuse activity of the antagonist muscles could 
perpetuate the activation of specific cell "fasciacytis", localized in the deep fascia as well in all the 
connective tissue [46], that produce HA. This excessive production can generate retention of the 
hyaluronic acid [47] in the connective tissue. Matteini P [48] has demonstrated that, by increasing the 
concentration of HA in a spread surface, HA can self-associate generating a dramatically increased 
of the viscoelasticity. The presence of higher viscosity extracellular matrix in a distal or proximal 
area, respect the primary spastic muscle, can altering the perimysium as well as the muscle spindles 
capsule that modulate the anulospiral ring. This impairment of the anulospiral ring could higher 
activate the afferent “Ia” fibers and then the alfa motoneurons with consequent spasticity in the 
corresponding motor unit. This cascade can “spread” the muscle stiffness or exacerbate the spasticity 
in patients also after months or years from the central lesion. 
We want to underline the importance of the location of the injections that should select muscles 
localized in different body segments that work in synergy or antagonism. The successful results of 
this study support our methodology that targets the restoration of the biomechanical of the full upper 
limb. The locations of the injections are also important due to the limit capacity of penetration of the 
Hyaluronidase. Indeed it can penetrate a fibrin barrier only if injected into it; otherwise, the drug 
diffuses around it and follows the path of least resistance [78]. It is important to know that the fascial 
planes and periostium are barrier to solutions containing hyaluronidase [73]. For this reason it is 
required a specific knowledge of the fascial planes to perform properly the injections.  
 
Study limitations: 
The limitations of this study are the possible effects of confounding variables. Another 
limitation is the small number of patients and the lack of a control group. For this reason we cannot 
be certain that the differences observed can be attributed solely to the effects of the hyaluronidase. 
Any suggestion of possible efficacy on some of the motor measures, that were previously outlined, 
could be spurious and indicate a placebo response, investigator bias, or other factors. 
The evaluation of the active movements have showed a moderate intra-operator rehabilitee 
due to the vicious patter of movements that the patients made during the evaluation. Since the 
movements were performed according to the participant preferences, we did not control how tasks 
were performed; thus, some variation in motion requirements were present.  
Improvements were also seen in other secondary outcome measures, such as activities of daily 
living. Most of these changes were clinically significant, and they might have important day-to-day 
benefits for patients. Nevertheless, caution must be exercised when interpreting the preliminary 
findings from this unblinded and uncontrolled study. Several treatments for spasticity that have 
appeared promising in open-label studies have failed to show efficacy under more rigorous controlled 




This open-label study provides preliminary evidence for the safety and potential symptomatic 
efficacy of hyaluronidase as a treatment for spasticity. If the purpose in relieving spasticity is to 
improve physical functioning and ultimately quality of life [83], hyaluronidase treatment will allow 
the decreasing of the spasticity without affect the functionality of the muscles. These results are very 
encouraging for develop a new treatment that allow the patients to improve the active movements. 
Unfortunately the medication by itself it is not efficacy if not injected in the correct points. The 
selection has to be performed through an accurate evaluation of the body following specific 
biomechanical criteria.  
Despite the limitations of our study, the data provide some insights for discussion and provide 
a justification for future research. A larger, prospective, controlled, double-blind, clinical trial is 
needed to assess further the findings from this preliminary study. Although we need to confirm these 
associations in a larger trial, disease severity and, specifically, the presence botulinum toxin 
unresponsive features might need to be taken into account when the entry criteria for patients are 
defined in future studies. 
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